Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 2Sarcoma, Synovial 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1PRETEXT I Hepatoblastoma 1Osteosarcoma 1Neurofibrosarcoma 1Neuroblastoma 1Lymphoma, Large-Cell, Anaplastic 1Localized Extraskeletal Ewing Sarcoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Ganglioneuroblastoma 1Fibrosarcoma 1Dermatofibrosarcoma 1Central Nervous System Neoplasms 1

Interventions

temsirolimus 1dehydroftorafur 1Vincristine 1Sirolimus 1Razoxane 1Platinum 1Liver Transplantation 1Irinotecan 1Fluorouracil 1Doxorubicin 1Dexrazoxane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × PRETEXT I Hepatoblastoma × Razoxane × Clear all
NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡